VNS Therapy Model 3100 Programmer, VNS Therapy Model 2000 Programming Wand
LivaNova USA, Inc. · Decision date Nov 25, 2025
What did the FDA approve?
FDA records P970003/S251 as a supplement to PMA P970003, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Nov 25, 2025.
FDA approval order statement
approval for a new version of the M3100 v2.0 Clinician Programmer update, including a new Pause Therapy function, new version of the M2000 v1.1.3.0 Wand, and updates to the Digital Product Platform
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Neurology
- Decision date
- Nov 25, 2025
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P970003/S251
- Regulatory pathway
- PMA supplement
- Applicant
- LivaNova USA, Inc.
- Product code
- LYJ
- Decision code
- APPR
- Decision date
- Nov 25, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, autonomic nerve, implanted for epilepsy.
- Applicant
- LivaNova USA, Inc.
- Product code
- LYJ
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P970003. Subsequent supplements may change the device or its indications.
FDA decision timeline
P970003 · Original PMA
VNS THERAPY SYSTEM
P970003/S251 received
Application receipt date recorded by FDA.
P970003/S248 · Related supplement
VNS Therapy System
P970003/S250 · Related supplement
VNS Therapy System
P970003/S251 · FDA decision
Real-Time Process
P970003/S252 · Related supplement
VNS THERAPY SYSTEM
P970003/S253 · Related supplement
VNS Therapy System
P970003/S249 · Related supplement
VNS Therapy System
P970003/S254 · Related supplement
VNS Therapy System
Timeline entries are records held by MedtechLedger for P970003. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P970003
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
VNS THERAPY SYSTEMP970003 | LivaNova USA, Inc. | PMA approval | Jul 16, 1997 | FDA |
VNS Therapy SystemP970003/S248 | LivaNova USA, Inc. | PMA supplement | Sep 5, 2025 | FDA |
VNS Therapy SystemP970003/S250 | LivaNova USA, Inc. | PMA supplement | Sep 12, 2025 | FDA |
VNS THERAPY SYSTEMP970003/S252 | LivaNova USA, Inc. | PMA supplement | Dec 17, 2025 | FDA |
VNS Therapy SystemP970003/S253 | LivaNova USA, Inc. | PMA supplement | Mar 4, 2026 | FDA |
VNS Therapy SystemP970003/S249 | LivaNova USA, Inc. | PMA supplement | Aug 12, 2026 | FDA |
VNS Therapy SystemP970003/S254 | LivaNova USA, Inc. | PMA supplement | Oct 2, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
LivaNova USA, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 100 Cyberonics Blvd., Houston, TX, 77058
Sources and methodology
- Original FDA record: P970003/S251
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



